The invention relates to a sensorized high throughput bioreactor, that can be placed in series and/or parallel with similar systems, to subject vascular conduits of different sizes to chemical-physical, mechanical and electromagnetic stimuli, simulating physiological and pathological conditions present within an organism.
The present invention provides an in vitro and ex vivo method using novel diagnostic probes with a specific spectrum detected by infrared (IR) spectroscopy.
The invention concerns a system based on a nano-transducer able to modify a target DNA sequence in a cell in order to delete harmful mutations underlying genetic diseases.
The invention consists of a novel experimental set-up for the muscular rehabilitation of the tongue, which is necessary for the restoration of motility and physiological function of the organ for the purpose of adequate swallowing in patients, who are post-stroke or otherwise have impaired tongue motility.
The present invention relates to the automation of data interpretation from a chromatography analysis, such specifically the retention times and concentration values of analytes in a mixture.
The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity, as well as immune-mediated inflammatory diseases and cancer.
The present invention relates to the development of novel benzofuran derivatives able to activate AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in the regulation of immune homeostasis
The present invention relates to novel benzo[d]isothiazolic-3(2H)-one-1,1-dioxide core compounds able to effectively and selectively inhibiting the IX and XII isoforms of the enzyme carbonic anhydrase (CA), which are predominantly expressed in hypoxic and metastatic tumors.
The object of the present invention is the design, synthesis, and pharmacological evaluation of novel diphenylmethane core molecules, capable of simultaneously promoting activation of the autophagy process and lipid catabolism, both in vitro and in vivo. Their dual activity may represent a novel approach for the treatment of neurodegenerative diseases, such as Alzheimer.
The present invention concerns the development of new derivatives with apoptosis-modulating action by inhibition of the MDM2/p53 complex.
